Diagnostic value for T2DM
venous plasma glucose :
•	> 7.0 mmol/L while fasting.
•	> 11.1 mmol/L without any lifestyle modification
HbA-1c :
•	Normal = <5.7 %	 (<39 mmol/mol)
•	Pre-DM = 5.7 % - <6.3 % (39-44 mmol/mol)
•	DM 	= ≥6.3 % 	 (≥45 mmol/mol)

Management of T2DM
At diagnosis of T2DM the following should be performed: 
› detailed history and physical examination, focusing on key issues which will affect treatment decision 
› baseline investigations to assess ASCVD* risk factors and complications of T2DM
Management is based on the results of the above. 
Management involves lifestyle modification, medications and patient education encouraging self-care and empowerment.
    * atherosclerotic cardiovascular disease

Targets for Control
Glycaemic control :			                                       mmol/L = VPG	
Venous Plasma Glucose :                                     mmol/mol or % = HbA-1c
•	4.4 mmol/L – 7.0 mmol/L (pre-prandial/fasting) 
•	4.4 mmol/L – 8.5 mmol/L (post-prandial)
HbA-1c :
•	< 7.0 % (for most)
•	≤ 6.5 % (for young, healthy, short duration of T2DM and no/minimal risk of hypoglycaemia)

Lipids :
•	Triglycerides = ≤ 1.7 mmol/L
•	HDL-C 
    o	Male = > 1.0 mmol/L
    o	Female = > 1.2 mmol/L
•	LDL-C = ≤ 2.6 mmol/L

Blood pressure :
•	130 – 139/70 – 79 mmHg (under normal circumstances)

Lifestyle changes :
•	150 mins/week of moderate-intensity exercise
•	75 mins/week of high-intensity exercise
•	Weight loss of ≥7%-10% of initial body weight within 6 months if BMI ≥ 25
•	Proper diet with foods with low GI (glycaemic index) 

Individualised HbA-1c targets based on different patient profiles
≤ 6.5 %
•	Newly and recently diagnosed
•	Younger age 
•	Healthier (no complications) 
•	Low risk of hypoglycaemia
6.6 % - 7.0 %
•	Normal circumstances
≥ 7.0 %
•	Elderly patients 
•	Presence of co-morbidities 
•	High risk of severe hypoglycaemia; hypo unawareness (unable to tell when blood glucose level drops to dangerous levels)
•	Short life expectancy

Recommendation for SMBG (self monitoring of blood glucose)
Mode of treatment	Breakfast	Lunch	    Dinner
	                Pre	Post	Pre	Post	Pre	Post
Diet only	        √	√	    -	√	    -	√
OGLDs	            √	√	    -	√	    -	√
Insulin	            √	√	    √	√	    √	√

Glucose Lowering Agents	                OD	Once a day
BiguanidesBD	                        BD Twice a day
1.	Metformin :                         OM	Once every morning
•	Formulation: 500/1000 mg 
    o	Minimum dose
    Initial dose: 500 mg OD 
    o	Maximum dose
    Usual dose: 1000 mg BD *Exception: 1000 mg TDS (follow doctor prescription)

2.	Metformin Sustained Release : (takes longer time to dissolve)
•	Formulation: 850 mg
    o	Minimum dose
    Usual dose: 850 mg BD 
    o	Maximum dose
    850 mg TDS

3.	Metformin Extended Release : (take much longer time to dissolve)
•	Formulation: 500/750/1000 mg
    o	Minimum dose
    Initial dose: 500 mg OD
    Usual dose: 2000 mg OD
    o	Maximum dose
    2000 mg OD

Sulphonylureas
1.	Glibenclamide :
•	Formulation: 5 mg 
    o	Minimum dose
    2.5	mg OD 
    o	Maximum dose
    10 mg BD

2.	Gliclazide :
•	Formulation: 80 mg 
    o	Minimum dose
    40 mg OM 
    o	Maximum dose
    160 mg BD

3.	Gliclazide Modified Release :
•	Formulation: 60/30 mg 
    o	Minimum dose
    30 mg OM 
    o	Maximum dose
    120 mg OM

4.	Glipizide :
•	Formulation: 5 mg 
    o	Minimum dose
    2.5 mg OM
    o	Maximum dose 
    10 mg BD

5.	Glimepiride :
•	Formulation: 2/3 mg 
    o	Minimum dose
    1 mg OM
    o	Maximum dose
    6 mg OM

Meglitinides
1.	Repaglinide :
•	Formulation: 0.5/1/2 mg 
    o	Minimum dose
    0.5 mg with main meal
    o	Maximum dose
    4 mg with main meals (not exceeding 16 mg daily)

α-glucosidase inhibitor
1.	Acarbose :
•	Formulation: 50/100 mg 
    o	Minimum dose
    Initial dose: 50 mg OD 
    Usual dose: 50-100 mg (take at 1st bite of main meals)
    o	Maximum dose
    100 mg TDS

Thiazolidinedione
1.	Rosiglitazone :
•	Formulation: 4/8 mg 
    o	Minimum dose
    4 mg OD 
    o	Maximum dose
    8 mg OD

2.	Pioglitazone :
•	Formulation: 15/30 mg 
    o	Minimum dose
    15 mg OD 
    o	Maximum dose
    45 mg OD

DPP4-inhibitors
1.	Sitagliptin :
•	Formulation: 25/50/100 mg 
    o	Minimum dose
    25 mg OD 
    o	Maximum dose
    100 mg OD

2.	Vildagliptin :
•	Formulation: 50 mg 
    o	Minimum dose
    50 mg OD 
    o	Maximum dose
    50 mg BD

3.	Saxagliptin :
•	Formulation: 2.5/5 mg 
    o	Minimum dose
    2.5 mg OD 
    o	Maximum dose
    5 mg OD

4.	Linagliptin :
•	Formulation: 5 mg 
    o	Minimum dose
    5 mg OD 
    o	Maximum dose
    5 mg OD

SGLT2-inhibitors
1.	Dapagliflozin :
•	Formulation: 5/10 mg 
    o	Minimum dose
    5 mg OD 
    o	Maximum dose
    10 mg OD

2.	Canagliflozin :
•	Formulation: 100/300 mg 
    o	Minimum dose
    100 mg OD
    o	Maximum dose
    300 mg OD

3.	Empagliflozin :
•	Formulation: 10/25 mg 
    o	Minimum dose
    10 mg OD 
    o	Maximum dose
    25 mg OD

4.	Luseogliflozin :
•	Formulation: 2.5/5 mg 
    o	Minimum dose
    2.5 mg OD 
    o	Maximum dose
    5 mg OD

5.	Ertugliflozin :
•	Formulation: 5/15 mg 
    o	Minimum dose
    5 mg OD
    o	Maximum dose 
    15 mg OD

GLP1-RA
1.	Exenatide Immediate Release :
•	Formulation: 5 μg/20 μL; 10 μg/40 μL 
    o	Minimum dose
    5 μg BD 
    o	Maximum dose
    10 μg BD

2.	Exenatide Extended Release :
•	Formulation: 2 mg 
    o	Minimum dose
    2 mg weekly
    o	Maximum dose 
    2 mg weekly

3.	Dulaglutide :
•	Formulation: 0.75 mg/1.5 mg 
    o	Minimum dose
    0.75 mg weekly
    o	Maximum dose
    1.5 mg weekly

4.	Liraglutide :
•	Formulation: 6 mg/mL 
    o	Minimum dose
    0.6 mg OD 
    o	Maximum dose
    1.8 mg OD

5.	Lixisenatide :
•	Formulation: 50 μg/mL; 100 μg/mL 
    o	Minimum dose
    10 μg OD
    o	Maximum dose
    20 μg OD

6.	Semaglutide :
•	Formulation: 0.25/0.5 mg 
    o	Minimum dose
    0.25 weekly
    o	Maximum dose 
    1.0 mg weekly

Treatment algorithm for newly diagnosed T2DM
HbA1c <6.5% AND FPG <6.0 mmol/L
•	Consider metformin monotherapy (only one form of medication)
•	if post prandial is > 11.0 mmol/L and/or metformin not tolerated, use:
    o	Meglitinide
    o	AGI (α-glucosidase inhibitor)
    o	DPP4-i (DPP4-inhibitors)

HbA1c 6.5-7.4% OR FPG 6.0-7.9 mmol/L
•	Mono or dual therapy with
    o	Metformin OR
    o	SU (Sulphonylureas)
    o	DPP4-i
    o	SGLT2-i (SGLT2-inhibitors)

HbA1c 7.5-8.4% OR FPG 8.0-9.9 mmol/L
•	Dual combination therapy with any combination of:
    o	Metformin 
    o	SU 
    o	Meglitinide 
    o	AGI 
    o	TZD (Thiazolidinedione)
    o	DPP4-i 
    o	GLP1-RA 
    o	SGLT2-i 
    o	Insulin

HbA1c 8.5-10.0% OR FPG 10.0-13.0 mmol/L
•	Triple combination therapy with any combination of:
    o	Metformin 
    o	SU 
    o	Meglitinide 
    o	AGI 
    o	TZD 
    o	DPP4-i 
    o	GLP1-RA
    o	SGLT2-i 
    o	Insulin

HbA1c >10.0% OR FPG >13.0 mmol/L
•	Basal/premixed insulin therapy + Combination therapy
            or
•	Intensive insulin therapy + OGLD

Treatment recommendations: Clinic follow-up
When HbA1c above individualised target with lifestyle modification + existing therapy
0.5%-1% above target :
•	Add 1 additional GLD from different class 
•	OR Intensification of insulin (if already on insulin)

1%-2% above target :
•	Consider 2 GLDs from different classes 
•	OR Intensification of insulin (if already on insulin)

>2% above target :
•	Initiation of insulin/GLP1-RA 
•	OR Intensification of insulin

Hypoglycaemia
•   impaired fasting glucose of 
    - < 3.9 mmol/L (VPG)
    - < 4.1 % (HbA1c)
    - < 21 mmol/mol (HbA1c)
    should serve as an alert for hypoglycemia
•   happens when blood glucose level is abnormally low
-   You are in risk of hypoglycaemia\nPlease consume something high in sugar or any medications issued by a doctor\nIf any symptoms such as dizziness or a headache are showing, please consult a doctor

Hyperglcaemia
•   impaired fasting glucose of 
    - 10 - 11.1 millimoles per liter (mmol/L) (VPG)
    - 7.9 - 8.6 % (HbA1c)
    - 63 - 70 mmol/mol (HbA1c)
    will show symptoms of hyperglycaemia
•   happens when blood glucose level is high for a prolonged time
-   You are in risk of hyperglycaemia\nPlease ensure you are not skipping any insulin doses issued by the doctor\nIf any symptoms such as nausea and vomitting are occuring, please consult a doctor immediately